December 28, 2022
December 28, 2022 —
UC San Diego study reveals critical insights into the complex biology of tissue-specific T cells, paving the way for a new branch of precision therapeutics in immunity, autoimmunity, and cancer.
December 13, 2022
December 13, 2022 —
UC San Diego scientists identify a new molecular model and potential therapeutic target for gout, the most common form of inflammatory arthritis.
November 28, 2022
November 28, 2022 —
UC San Diego researchers identify the PKCα enzyme as a promising therapeutic target in Alzheimer’s disease; a mutation that increases its activity led to biochemical, cellular and cognitive impairments in mice.
November 22, 2022
November 22, 2022 —
The UC San Diego Sanford Stem Cell Institute leads its first space launch, sending stem cells into space aboard the International Space Station. The NASA-partnered study will take advantage of the microgravity environment of space to study accelerated aging in stem cells.
November 21, 2022
November 21, 2022 —
UC San Diego Alpha Stem Cell Clinic awarded $8M to expand clinical trials of novel stem cell therapies. The CIRM award will advance partnerships between academic and industry experts in San Diego to expedite clinical trials for patients with difficult-to-treat diseases.
November 18, 2022
November 18, 2022 —
UC San Diego researchers used human brain organoids to study the effects of prenatal alcohol exposure on neural development, revealing significant harms in molecular detail.
October 31, 2022
October 31, 2022 —
Researchers at UC San Diego report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer, which kills more than 34,000 men in the U.S. annually.
October 31, 2022
October 31, 2022 —
UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.
October 27, 2022
October 27, 2022 —
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
October 3, 2022
October 3, 2022 —
UC San Diego study finds enhanced PKCγ activity drives spinocerebellar ataxia type 14; suggests inhibiting the enzyme may have therapeutic potential
